Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRE-EMPT
NCT07232069Phase 3Recruiting
- Sponsor
- Duke University
- Start
- Jul 2026
- Primary completion
- Jul 2031
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of rosuvastatin, colchicine in atherosclerosis, sponsored by Duke University. Started Jul 2026; status: recruiting.
02
Drugs
rosuvastatincolchicine
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT07232069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232069.